ABSTRACT
Aim To establish a cell model to detect the activity of somatostatin (SST) by targeting somatostatin receptor 2 (SSTR2), and to provide a simple and stable evaluation method for the drug screening of SSTR2 agonists and somatostatin analogues (SSTA). Methods The target gene of SSTR2 was integrated into the pEGFP-N3 vector, and the recombinant plasmid was constructed and transfected into HEK293 cells. After G418 screening, positive clone was selected and the stable cell lines were obtained by expanding culture. The stable cell lines were identified by fluorescence cell imaging, Western blot and qPCR. A calcium flow detection system was established to optimize cell number, fluorescence dye concentration and incubation time. Finally, the screening model was used to detect the different batches of the marketed somatostatin preparation Stilamin. Results SSTR2 stable cell lines were successfully constructed, and the receptors were mainly distributed on the cell membrane. The optimal conditions for calcium flow detection were determined as follows; 30 000 cells/Well, Fluo-4/AM indicator concentration was 3 p,mol • L -1 ~5 u,mol • L-1 , incubation time was 45 min. Under this condition, EC50 value of Stilamin in different batches was stable. Conclusions SSTR2 overexpressed stable cell lines are successfully constructed and calcium flow detection method is optimized to provide a simple and stable model for the screening of somatostatin receptor agonists.
ABSTRACT
Objective To discuss the clinical effect of montelukast in the treatment of cough after infection. Methods 100 cases of patients with cough after infection in Taizhou hospital from January 2016 to February 2017 were randomly divided into the experimental group and the control group, 50 cases for each group, the control group was given oral Tianyi Zhike tangjiang liquid, the experimental group was given montelukast sodium on the basis of the control group, the treatment effect and cough integral between two groups after infection were compared and analyzed. Results The clinical effective rate of the experimental group was 96.0%, significantly higher than the control group 70.0%, the differences between groups was statistically significant (P<0.05). Cough scores in the experimental group after the treatment were significantly better than the control groupwith statistical significance (P<0.05). Conclusion Montelukast in the treatment of cough after infectious has clear clinical effect, and high safety.
ABSTRACT
Objective To discuss the clinical effect of montelukast in the treatment of cough after infection. Methods 100 cases of patients with cough after infection in Taizhou hospital from January 2016 to February 2017 were randomly divided into the experimental group and the control group, 50 cases for each group, the control group was given oral Tianyi Zhike tangjiang liquid, the experimental group was given montelukast sodium on the basis of the control group, the treatment effect and cough integral between two groups after infection were compared and analyzed. Results The clinical effective rate of the experimental group was 96.0%, significantly higher than the control group 70.0%, the differences between groups was statistically significant (P<0.05). Cough scores in the experimental group after the treatment were significantly better than the control groupwith statistical significance (P<0.05). Conclusion Montelukast in the treatment of cough after infectious has clear clinical effect, and high safety.